Blueprint Medicines Corporation Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

Blueprint Medicines Corp (NASDAQ:BPMC) – Equities researchers at Wedbush upped their Q1 2020 EPS estimates for Blueprint Medicines in a research note issued to investors on Tuesday, April 28th. Wedb

Leerink Partners analyst Andrew Berens maintained a Buy rating on Seattle Genetics (SGEN) today and set a price target of $155.00. The company's shares

Leerink Partners analyst Andrew Berens maintained a Buy rating on Seattle Genetics ( SGEN – Research Report ) today and set a price target of $155.00 . The company’s shares closed last Friday at $

Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

Vertex (VRTX) rides high on earnings and revenue beat in Q1.The company raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

Morgan Stanley analyst David Lebovitz maintained a Buy rating on Blueprint Medicines (BPMC) today and set a price target of $88.00. The company's shares

Morgan Stanley analyst David Lebovitz maintained a Buy rating on Blueprint Medicines ( BPMC – Research Report ) today and set a price target of $88.00 . The company’s shares closed last Thursday a

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney disease, today announced the appointment of Kyle

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC) and Blueprint Medicines (BPMC) with bullish

Blueprint Medicines Corp (NASDAQ:BPMC) gapped down before the market opened on Wednesday after JMP Securities lowered their price target on the stock from $107.00 to $103.00. The stock had previously

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Hormel Foods, Tyson Foods and Zebra Technologies, on Wednesday. HIGHLIGHTS

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dexcom (DXCM), Centene (CNC) and Blueprint Medicines (BPMC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dexcom ( DXCM – Research Report ), Centene ( CNC – Research Report ) and Blueprint Medicines ( BPMC